Skin Cancer

The AJMC® Skin Cancer compendium is a comprehensive resource for clinical news and expert insights about melanoma and other skin cancers.

Latest News

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com

RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

July 24th 2025

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval

FDA | Image credit: Postmodern Studio.jpeg

FDA Issues CRL for Vusolimogene Oderparepvec in Advanced Melanoma

By Pearl Steinzor

July 22nd 2025

UV Safety Awareness Month | Image Credit: Nass Studio - stock.adobe.com

Sun Exposure Risks Brought to Light During UV Safety Awareness Month

By Brooke McCormick

July 1st 2025

Outside of patient diversity, the researchers call for variety in data types to strengthen AI models, with a compilation of patient records with genomic data and images. | Image credit: natali_mis - stock.adobe.com

Challenges and Opportunities for AI in Melanoma Detection

By AJMC Contributor

July 1st 2025

Whole-exome sequencing would help define mutations tied to micrometastasis and help further refine risk stratification. | Image credit: Seventyfour - stock.adobe.com

Mitotic Rate, Lymphovascular Invasion Among Risk Factors for Relapse in Melanoma

By Jared Kaltwasser

June 25th 2025

Dr. Jason Luke leads a panel discussing immunotherapy advances in Cutaneous and Basal Cell Carcinoma

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Graphic representing the top 5 skin cancer articles for 2022

December 23rd 2022

Top 5 Most-Read Skin Cancer Articles of 2022

BRAF mutations were addressed in depth this year, having been mentioned in 3 of this year’s top 5 articles. Also discussed were a first-in-its-class combination treatment approval and potential indicators of increased skin cancer risk.

Image of researchers investigating for skin cancer

December 21st 2022

Novel, Nonsurgical BCC Treatment Shown Safe and Effective

In this study, researchers treated 37 basal cell carcinoma (BCC) lesions from 30 patients, with follow-ups at 5 time points after baseline examination.

What We're Reading

December 14th 2022

What We’re Reading: mRNA Vaccine Effective Against Melanoma; Proposed Addiction Treatment Policy; Maternal Health Disparities Before Abortion Bans

Moderna’s mRNA-4157/V940 combined with Merck’s pembrolizumab reduced melanoma recurrence and death; HHS proposed permanently implementing emergency opioid use disorder policies enacted in 2020; maternal death rates were 62% higher in 2020 in states that now have abortion restrictions.

Abstract image of clinical data

December 10th 2022

Real-world Data Demonstrate Strength, Durability of Checkpoint Inhibitor Use in cSCC

Response, progression-free survival, overall survival, time-to-next-treatment, and toxicity outcomes were evaluated among patients with advanced cutaneous squamous cell carcinoma (cSCC) who received first-line treatment with immune checkpoint inhibitors.

Image of examination for skin cancer

November 29th 2022

Lack of Knowledge Continues to Influence Delayed Melanoma Diagnosis

Malignant cutaneous melanoma outcomes were investigated as they relate to diagnosis delay and potential influence from socioeconomic and demographic factors in Brazil, where skin cancer diagnoses represent 30% of all cancer diagnoses.

Image of a transplant surgery

November 24th 2022

Risk of Subsequent Skin Cancer Seen Among Organ Transplant Recipients

The study's goal was to clarify possible second and third skin cancer development patterns among organ transplant recipients who developed more than 1 instance of skin cancer and to better characterize this patient population by patient age and transplanted organ type.

Close-up image of face

November 16th 2022

Cryosurgery Effective Against BCC Relapse, but Further Study Required

While immunocryosurgery is known to be effective against primary nonsuperficial basal cell carcinoma (BCC), there is less data on its effectiveness in relapsed BCC.

Image of melanoma

November 10th 2022

Revised Classification Criteria Needed Due to Melanoma Overdiagnosis

The increasing rate of melanoma diagnosis may not be due to actual disease, the authors of a new study posit; instead, it may be due to overdiagnosis of patients with an actual very low risk of death.

Image of the human body and some organs

October 27th 2022

Organ Transplant Patients at Higher Risk of BCC vs the General Population

This investigation compared the histologic features of basal cell carcinoma (BCC) between organ transplant recipients and the general population.

Image of cancer-genetics link

October 22nd 2022

Neurofibromatosis Type 1 Linked to Greater Skin Cancer Risk

The risks of 4 types of skin cancers were investigated among patients who have neurofibromatosis type 1, a multisystem autosomal dominant genetic syndrome characterized by loss of neurofibromin.

Dermatologist using a dermatoscope

October 11th 2022

Review Finds Dermoscopy Can Reduce Incomplete Excision of Skin Cancer

Dermoscopy is a relatively inexpensive and readily available tool that can improve outcomes and quality of life for patients who need surgical excision of nonmelanoma skin cancers, the authors found.

Image of a doctor examining a patient's neck

October 7th 2022

Certain Patients Who Have BCC May Benefit From Electrochemotherapy

Electrochemotherapy in basal cell carcinoma (BCC) was evaluated for its utilization practicality, efficacy, and safety, as well as factors that may predict disease response to the treatment.

Image of basal cell carcinoma

September 30th 2022

Advanced Imaging System Investigated for Faster Diagnosis of Skin Cancers

This new study explored the diagnostic utility and accuracy of 2-photon fluorescence microscopy (TPFM) among nonmelanoma skin cancers, which included basal cell carcinoma and squamous cell carcinoma.

Examining for skin cancer

September 27th 2022

Postsurgical Positive Margins Top Indicator of BCC Recurrence

This new study investigated risk factors for basal cell carcinoma (BCC) recurrence in the head and neck region.

Dermoscopy Holds Limited Potential to Differentiate BCC From Benign Tumors

September 24th 2022

Dermoscopy Holds Limited Potential to Differentiate BCC From Benign Tumors

Christina Mattina

Despite some differences in the frequency of dermoscopic features between basal cell carcinoma (BCC) and benign skin tumors, dermoscopy alone is not sufficient for a reliable diagnosis, according to a recent study.

albino skin

September 19th 2022

Squamous, Basal Cell Carcinoma Top Skin Cancers Among Persons With Albino Skin

Previous study results on incidence of skin cancers in persons with albino skin who live in Africa have been inconsistent, despite this population having a known higher risk for the disease.

Igor Puzanov, MD, Jacobs School of Medicine and Biomedical Sciences and Roswell Park Comprehensive Cancer Center

September 12th 2022

Dr Igor Puzanov Discusses the State of Adjuvant Therapy for Advanced Melanoma

In this interview with The American Journal of Managed Care® (AJMC®), Igor Puzanov, MD, of Roswell Park Comprehensive Cancer Center and Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, discusses the state of treatment selection in the setting of resected advanced melanoma, why sequencing of therapies does not occur in the setting of adjuvant therapy, and best practices to keep in mind for patient education and managing their treatment-related toxicities.

Image of clinical research

September 7th 2022

More Study Needed on Melanoma Risk From Methotrexate

Quantifying the risk of malignant melanoma from methotrexate use proved difficult in this new study, with the authors calling for larger studies with longer follow-up to guide future practice in the space.

Image of skin cancer

August 31st 2022

Dermoscopy May Be More Accurate vs Incisional Biopsy for Melanoma Thickness

In this new study, investigators searched for potential predictors of melanoma thickness, with implications for treatment decisions regarding biopsy and excision margins.

Sigrun Hallmeyer, MD

August 24th 2022

Dr Sigrun Hallmeyer Highlights Clinical Achievements and Barriers in Melanoma

In this interview with The American Journal of Managed Care®, Sigrun Hallmeyer, MD, medical director of Advocate Lutheran General Hospital’s Cancer Service Line and co-director of medical research at Advocate Aurora Health, in Illinois, touches on several important topics within the melanoma space.

Patient learning about skin cancer

August 17th 2022

Skin Cancer Knowledge Suboptimal Among Patients

Adult patients from dermatology clinics affiliated with 2 Midwest universities were evaluated for their ability to differentiate skin cancer by sight and for their skin cancer knowledge.

Image of a slide under a microscope

August 13th 2022

Second Opinions Likely Influenced by Initial Dermatopathology Diagnosis

This study investigated how an initial diagnosis influences delivery of second opinions concerning skin cancers, including the possibility of an incorrect diagnosis.

Image of a skin cancer cell

August 10th 2022

SLN Biopsy Promising for Long-term Metastatic Melanoma Control

The usefulness of sentinel lymph node (SLN) biopsy was investigated among patients with melanoma and SLN metastases.

Image of a transplant operation

August 2nd 2022

Risk of Keratinocyte Carcinoma Increases With Pediatric Solid Organ Transplant

This new study investigated keratinocyte carcinoma mortality and morbidity rates following pediatric solid organ transplant. Little is known on these associations in pediatric patients; more is known of these outcomes among adult patients.

Image of an exam for skin cancer

July 29th 2022

Margin Size Associated With Risk of Local Recurrence From Melanoma In Situ

This new study, conducted among persons living with melanoma in situ, investigated the possibility of identifying clinicopathological predictors of local recurrence.

Image of potential skin cancer

July 25th 2022

Reflectance Confocal Microscopy Improves Skin Cancer Diagnosis in New Trial

This prospective study on reflectance confocal microscopy, a high-resolution and noninvasive form of imaging for skin cancer, investigated if the diagnostic method could improve accuracy results by 30% following dermoscopy.

Vernon Sondak MD

July 22nd 2022

Dr Vernon Sondak on BRAF Mutations in Metastatic Melanoma

In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating patients with melanoma with BRAF mutations, including those whose disease has spread to the brain or other sites.

Image of the word "melanoma"

July 21st 2022

Pediatric, Adolescent Melanoma Uptick Seen in Finland

Although melanoma incidence has been reported in Europe overall for the past several decades, specific numbers on the cancer’s incidence in Finland, as well as disease trends, have remained unknown.

Image of an older man

July 16th 2022

Use of Local Skin Flaps May Lead to Reduced Risk of Scarring Following Mohs Surgery

Three methods of cosmetic surgery—local skin flap, full thickness skin graft, and secondary intention—were evaluated for their scarring risk following Mohs microscopic surgery on the distal third of the nose.

Georgina V. Long, MBBS, PhD

July 14th 2022

KEYNOTE-716: First Data on DMFS Show Additional Pembrolizumab Benefit in Patients With Melanoma

New date from the KEYNOTE-716 trial show distant metastasis-free survival benefit from pembrolizumab use in melanoma.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions